Lilly Endowment Inc. has completed a series of transactions involving the sale of Eli Lilly & Co. (NYSE:LLY) common stock, according to data disclosed in a recent SEC Form 4 filing. The sales, which took place on May 6, 2026, involved a total of 15,828 shares and represented a total value of roughly $15.75 million.
The liquidation was executed through several distinct transactions at varying price levels. A block of 13,620 shares was sold at a weighted average price of $995.225, with individual transaction prices spanning from $995.00 to $995.9963. Furthermore, an additional 2,208 shares were transacted at a weighted average price of $996.183, with specific prices ranging between $996.00 and $996.46 per share.
Company Profile and Market Position
Eli Lilly & Co. remains a dominant force in the pharmaceutical sector, currently boasting a market capitalization of $867.66 billion. The company is trading at a price-to-earnings (P/E) ratio of 34.76. Financial performance indicators show significant momentum, with the company delivering a revenue growth rate of 47% over the last twelve months as of the first quarter of 2026.
Following these recent divestments, Lilly Endowment Inc., which is identified in the filings as a former 10% shareholder, continues to hold a massive position of 91,881,150 shares of Eli Lilly & Co. common stock directly.
Operational Expansion and Clinical Developments
Parallel to these ownership changes, Eli Lilly has announced major capital deployment strategies in the United States. The company is committing $4.5 billion toward its facilities in Lebanon, Indiana. This move brings the total capital commitments made by the firm in the state to more than $21 billion since 2020. These funds are designated for the advancement of Lilly Lebanon API and the establishment of Lilly Lebanon Advanced Therapies, which will serve as the company's inaugural manufacturing site for genetic medicines.
In clinical news, the company reported long-term data regarding its treatment for ulcerative colitis. In a study involving the drug Omvoh, 63.5% of patients were able to maintain disease clearance over a four-year period, with that percentage sustaining remission.
Financial Returns and Analyst Outlook
Regarding shareholder returns, Eli Lilly has declared a quarterly dividend of $1.73 per share for the second quarter of 2026. This dividend is scheduled to be paid on June 10, 2026, to shareholders of record as of May 15, 2026.
The investment community maintains a generally positive outlook on the stock. RBC Capital has reiterated an Outperform rating for Eli Lilly, noting that liver safety data from clinical trials remains consistent with expectations. Additionally, Goldman Sachs has maintained its Buy rating on the company. These ratings persist despite reports within the FDA Adverse Event Reporting System regarding one instance of hepatic failure in a patient following the use of Foundayo.